Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Denosumab/ipilimumab/nivolumab

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Peric L, et al. DUAL IMMUNOTHERAPY FOR THE TREATMENT OF METASTATIC KIDNEY CANCER IN A PATIENT UNDERGOING HEMODIALYSIS. Libri Oncologici 51 (Suppl. 1): 10-12 abstr. S5, 2023. Available from: URL: https://hrcak.srce.hr/file/433139 [abstract] Peric L, et al. DUAL IMMUNOTHERAPY FOR THE TREATMENT OF METASTATIC KIDNEY CANCER IN A PATIENT UNDERGOING HEMODIALYSIS. Libri Oncologici 51 (Suppl. 1): 10-12 abstr. S5, 2023. Available from: URL: https://​hrcak.​srce.​hr/​file/​433139 [abstract]
Metadaten
Titel
Denosumab/ipilimumab/nivolumab
Lack of efficacy: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41412-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Carfilzomib

Case report

Denosumab

Case report

Osimertinib

Case report

Toripalimab